MGC yesterday received Ethics Committee approval for the Phase III Clinical Trial (‘the Trial’) of CimetrA™ on Patients Diagnosed with COVID-19 (SARS-CoV-2). CimetrA™ is designed with the scientific aim to target viral infections with inflammatory complications.
Having already been successfully evaluated on infected patients in a double-blind placebo-controlled, Phase II clinical trial. Although a significant initial worldwide supply agreement has already been signed for ArtemiC™ Rescue in its form of a food supplement, the product has now also undertaken a name change to CimetrA™, in recognition of the transfer of its status to an Investigational Medicinal Product (‘IMP’) ahead of the Trial’s commencement. Importantly in this respect, CimetrA™ encapsulates Graft Polymer Limited’s GraftBio™ SNEDDS technology (Self-Nano Emulsifying Drug Delivery System), as a unique platform to deliver higher concentrations of the natural active ingredients more effectively in to the cells, thereby improving their bioavailability.
We would draw your attention to the various disclaimers in the document both at the beginning and at the end of the note. Retail clients (as defined by the rules of the FCA) must not rely on the research document. In particular you should note that the research document is a non-independent marketing communication. The analyst who has prepared the research is aware that TPI provides research to MGC Pharmaceuticals Limited. Accordingly the research has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibitions on dealing ahead of its dissemination.
The information in the document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.
Copyright © 2021 Turner Pope Investments (TPI) Limited, all rights reserved.
